Copyright
©The Author(s) 2022.
World J Gastrointest Oncol. Mar 15, 2022; 14(3): 724-733
Published online Mar 15, 2022. doi: 10.4251/wjgo.v14.i3.724
Published online Mar 15, 2022. doi: 10.4251/wjgo.v14.i3.724
Table 2 The data of all 253 cases that received radiofrequency ablation and completed follow-ups
| Follow-up period | n | Curative, n (%) | Relapse, n (%) | Recurrence, n (%) | Progression, n (%) |
| 3 mo | 253 | 236 (93.3) | 17 (6.7) | 18 (7.1) | 2 (0.8) |
| 6 mo | 208 | 193 (92.8) | 15 (7.2) | 11 (5.3) | 0 |
| 1 yr | 141 | 129 (91.5) | 12 (8.5) | 14 (9.9) | 0 |
| 2 yr | 93 | 84 (90.3) | 9 (9.7) | 8 (8.6) | 1 (1.1) |
| 3 yr | 61 | 54 (88.5) | 7 (11.5) | 6 (9.8) | 2 (3.3) |
| 4 yr | 28 | 24 (85.7) | 4 (14.3) | 4 (14.3) | 0 |
| 5 yr | 6 | 5 (83.3) | 1 (16.7) | 1 (16.7) | 0 |
- Citation: Wang NJ, Chai NL, Tang XW, Li LS, Zhang WG, Linghu EQ. Clinical efficacy and prognostic risk factors of endoscopic radiofrequency ablation for gastric low-grade intraepithelial neoplasia. World J Gastrointest Oncol 2022; 14(3): 724-733
- URL: https://www.wjgnet.com/1948-5204/full/v14/i3/724.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v14.i3.724